BiotechTube

PXVX0200 Lot A + PXVX0200 Lot B + PXVX0200 Lot C + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cholera

Conditions

Cholera

Trial Timeline

May 1, 2014 → Jun 1, 2015

NCT ID
NCT02094586

About PXVX0200 Lot A + PXVX0200 Lot B + PXVX0200 Lot C + Placebo

PXVX0200 Lot A + PXVX0200 Lot B + PXVX0200 Lot C + Placebo is a phase 3 stage product being developed by Bavarian Nordic for Cholera. The current trial status is completed. This product is registered under clinical trial identifier NCT02094586. Target conditions include Cholera.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02094586Phase 3Completed

Competing Products

9 competing products in Cholera

See all competitors
ProductCompanyStageHype Score
AzithromycinPfizerPhase 3
76
Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole CellSanofiPhase 3
76
Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole CellSanofiApproved
84
CiprofloxacinBayerPhase 3
74
PXVX0200 + placeboBavarian NordicPhase 3
74
PXVX0200 + PlaceboBavarian NordicPhase 3
74
VAXCHORA (Cholera Vaccine, Live, Oral)Bavarian NordicApproved
82
PXVX0200 + PlaceboBavarian NordicPhase 1
30
PXVX0200 10E8 + PXVX0200 10E9 + Placebo + ShancholEmergent BioSolutionsPhase 2
44

Other Products from Bavarian Nordic

IMVAMUNE®Approved
82
VAXCHORA (Cholera Vaccine, Live, Oral)Approved
82
PROSTVAC-V + PROSTVAC-F + GM-CSF + PlaceboPhase 3
74
PXVX0200 + placeboPhase 3
74
MVA-BN standard regimen + MVA-BN standard regimen (Administered as PEP)Phase 3
74